Advances in Targeted Therapies in Cancer (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 5542
Special Issue Editor
Interests: experimental; therapeutics; identification of novel molecular targets related to cell survival pathways, signaling pathways such as EF2-Kinase (EF2K), FOXM1, AXL, and KRAS signaling; RNA (siRNA, miRNA, lncRNA) therapeutics; nanotherapeutics/nanodelivery systems (lipid, polymer and metal-based); development of tumor targeted therapies, kinase inhibitors, immunotherapy; immunosuppressive tumor microenviorenment; tumor associated macrophages
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, the focus of new drug development has shifted towards identifying and targeting molecular drivers of cancer. Targeted therapies have led to remarkable breakthroughs in cancer treatment and have allowed for the completion or continued clinical trials of new agents for the treatment of patients with advanced cancer. In molecular-based, targeted cancer therapy, the proteins or genes that drive the tumor growth and progression processes are targeted, thereby interfering with a variety of oncogenic cellular processes. Monoclonal antibodies are commonly used as therapeutic agents for challenging various targets at the cell surface by interfering with oncogenic signaling pathways and immunotherapy as immune check point inhibitors, which recently revolutionized the cancer therapy. Small molecule inhibitors are used to target intracellular kinases or other key proteins that regulate cell signaling, or other signaling pathways are utilized for the treatment of primary, metastatic, and advanced therapy-resistant cancers, and currently more than 40 small molecule inhibitors have received approval from the FDA for the treatment of cancer. A wide variety of targets are currently under investigation, including those related to protein–protein interactions, cancer metabolism, and immune modulation. RNA interference (RNAi)-based therapeutics have been proven to have a great potential for the development of targeted therapies for cancer. Small interfering RNA (siRNA) and microRNA (miRNA) can inhibit the expression of any cancer-related genes/mRNAs. They have both entered clinical trials and, recently, three novel siRNA-based therapeutics were approved by the FDA. In addition, nanotechnology and nanotherapeutics proved to be extremely effective in enhancing the efficacy of conventional and targeted therapies and reducing the toxicity. Moreover, in recent years, cell-based therapies, including chimeric antigen receptor (CAR)-T cell therapy, natural killer (NK) cell therapy, dendritic cell (DC) therapy, and stem cell therapy, have also emerged as significant modalities in advanced targeted cancer therapy by targeting and eliminating malignant cells. We are pleased to invite you to a Special Issue entitled “Advanced in Targeted Therapies in Cancer” to highlight recent development in cancer therapies.
This Special Issue aims to provide insights into the strategies for advanced targeted therapies in cancer in the aspects of antibody-based therapies, small molecule inhibitors, RNAi-based therapies, and cell-based therapies, addressing the fundamentals of the approaches, challenges, recent preclinical and clinical studies, and state-of-the-art and future perspectives.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: targeted cancer therapy, small molecule inhibitors, antibody-based cancer therapies, non-coding RNA therapies (i.e., miRNA and siRNA), cell-based therapies, nanotherapeutics, cell-based therapies, such as chimeric antigen receptor (CAR)-T cell therapy, natural killer (NK), CAR-NK cell therapy, and dendritic cell (DC) therapies.
I look forward to receiving your contributions to the Special Issue.
Dr. Bulent Ozpolat
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- cancer, antibody therapy
- small molecule inhibitor
- RNAi therapy
- cell-based therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
